Abstract: Ascorbyl-GLA or Ascorbyl-DGLA in medicaments for treatment of asthma and other disorders.

Abstract: A method of treating Huntington's Chorea by the administration of effective amounts of GLA or DGLA and a method of delaying the onset of Huntington's Chorea or preventing it altogether by administering appropriate amounts of GLA or DGLA to clinically normal individuals who are genetic carriers of the disease, and a method of preparation of medications for such purpose using such acids.

Abstract: A method of treatment of a disorder, including breast cancer and other cancer, with effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-y or 22:5n-6) and one or more of the metabolites of .alpha.-linolenic acid (18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3 or 22:6n-3) administered as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto alone or in acceptable pharmaceutical carrier or diluent.

Abstract: Method of stabilizing polyunsaturates by adding thereto (i) ascorbic acid or an ester or salt thereof, and (ii) a phosphorylated mono- or di-fatty acyl glyceride or a salt thereof, and optionally a tocopherol or tocotrienol antioxidant, and a method of preparing stable pharmaceutical, nutritional or veterinary compositions.

Abstract: A triglyceride for use in therapy or as a nutritional supplement, or a composition containing a triglyceride, wherein the triglyceride comprises a fatty acid selected from gamma-linolenic acid and the n-6 EPAs naturally derived therefrom and stearidonic acid and the n-3 EFAs naturally derived therefrom, forming a triple ester with glycerol or alternatively forming a double ester in which the other esterifying acide is a single residue of linoleic acid, with the proviso that the di-gammalinolenoyl-mono-linoleoyl glyceride if selected is used as a preparation containing more than 20% by weight thereof.

Abstract: A natural vitamin E preparation, i.e. vitamin E extracted from natural sources, comprising one or more of the alpha-, beta-, gamma- and delta-tocopherol forms, either as the tocopherol itself, or as a derivative, such as the acetate, in which the total concentration of Wendt PAHs is less than 100 ppb.

Abstract: Atopic eczema, breast pain or premenstrual syndrome are treated by administering to a person in need of same a composition containing at least 20% di-linoleoyl-mono-gamma-linolenyl glycerol by weight.

Abstract: Increasing gut calcium absorption in humans or animals by the administration of GLA, DGLA or LA as such or in salt or other pharmacologically acceptabe form, optionally in association with EPA, DHA or other EFA in similar forms, specifically useful in treatment of osteoporosis.

Abstract: Pharmaceutical and nutritional compositions are disclosed containing, in association with a suitable diluent or carrier, at least 10% by weight of a cholesterol fatty acid ester where the fatty acid is gamma-linolenic acid, dihomo-gamma-linolenic acid, adrenic acid, the 22:5 n-6 acid, stearidonic acid, the 20:4 n-3 acid, eicosapentaenoic acid, docosahexaenoic acid, the 22:5 n-3 acid or columbinic acid. Novel cholesterol columbinic acid esters are described.

Abstract: An NSAID in the form of a compound with an essential fatty acid or essential fatty acid alcohol, particularly an NSAID as listed in categories 1 to 9 herein. Further, a method of preparation of a medicament for the treatment including prophylatic treatment of rheumatoid arthritis, osteoarthritis and related disorders; dysmenorrhoea; dementias, including Alzheimer's disease; or any other inflammatory or other conditions specified herein, wherein the said NSAID is used.

Abstract: Damage to internal tissues, and particularly to the central nervous system as a consequence of exposure to ionizing radiation is prevented or treated by administration of GLA and/or DGLA. Medicaments containing GLA and/or DGLA for such treatment or prevention may also further comprise EPA and/or DHA.

Abstract: Preparation of a formulation for mitigating ill effects of smoking, wherein one or more of the n-6 EFAs selected from GLA, DGLA and AA, and one or more of the n-3 EFAs selected from SA, 20:4n-3, EPA, DPA or DHA are used, preferably so that the daily dose of each fatty acid is within the range 1 mg to 100g/day. The formulation may in many other purposes be used in the treatment or prevention of ageing of the skin of smokers.

Abstract: Prevention and/or treatment of abnormal calcification in any tissue by the administration of (i) GLA and/or its EFA metabolites, and in particular the rapidly produced DGLA and/or (ii) EPA and/or its precursors, stearidonic acid and 20:4 n-3, and metabolites, docosahexaenoic acid (DHA) or docosapenmenoic acid (22:5 n-3), as such or in salt or other pharmacologically acceptable form. This is especially suitable for prevention or treatment of nephrocalcinosis and/or renal stones.

Abstract: The negative symptoms of schizophrenia and/or low cell membrane levels of EFAs may be treated with a combination of arachidonic acid and docosahexaenoic acid.

Abstract: Method of safe intravenous administration of fatty acid(s), and in particular the n-6 and n-3 series essential fatty acids and conjugated fatty acids, whereby the fatty acid(s) or a proportion thereof are administered in the form of lithium salts, and whereby the plasma lithium levels are regularly monitored to avoid haemolysis, preferably keeping the lithium level no higher than 0.7 millimolar in the long term and preferably also no higher than 0.4-0.5 millimolar in the first 24-48 hours or, where only a proportion of the fatty acids are administered as lithium salts, a corresponding proportion of said levels.

Abstract: A phospholipid comprising two different unsaturated fatty acids, the fatty acids being selected from the twelve n-6 and n-3 essential fatty acids, oleic acid, parinaric acid and combinic acid.

Abstract: Gamma-linolenic (GLA) and/or dihomo-gamma-linolenic acid (DGLA) may be used in the treatment of vulvar dystrophy and/or vaginal dryness. Other essential fatty acids of the n-6 or n-3 series may also be used in association with GLA and/or DGLA.

Abstract: Gamma-linolenic acid and/or dihomo-gamma-linolenic acid is used in a medicament for reducing the rate of reocclusion of an artery from which an occlusion or other blockage has been removed, or for preventing occlusion of peripheral or coronary arteries. The medicament may also comprise eicosapentaenoic acid.

Abstract: The invention provides pharmaceutical and disinfectant compositions containing lithium salts of C.sub.18-22 polyunsaturated fatty acids. The compositions may be used in the treatment of conditions responsive to lithium and/or polyunsaturated fatty acid therapy, in parenteral alimentation or food supplements or in surface disinfection to combat transmission of viral diseases.